Polio Vaccine: Salk & Sabin's Mass Immunization Explained

In 1952, American hospitals recorded more than 21,000 cases of paralytic polio in a single year, and wards of children lay inside iron lungs because their breathing muscles had stopped working. Three years later, Jonas Salk's injected vaccine arrived, and within a decade Albert Sabin's oral vaccine joined it. Together they turned a seasonal terror into a disease that wild virus now causes in only two countries. This article explains how each polio vaccine works, what the evidence showed, where the programs went wrong, and why the last cases are so hard to end.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

Key Takeaways

• Poliovirus infects through the mouth and multiplies in the gut; fewer than 1 in 100 infections in children causes paralysis, but that paralysis is permanent.
• Salk's vaccine (IPV) uses virus killed with formaldehyde and is injected. Sabin's vaccine (OPV) uses weakened live virus and is swallowed.
• The 1954 field trial involved about 1.8 million children and was announced on April 12, 1955. A manufacturing failure at one company, the Cutter incident, nearly derailed it weeks later.
• Wild poliovirus types 2 and 3 have been declared eradicated; type 1 caused 99 cases in 2024, all in Afghanistan and Pakistan.
• The live vaccine can, rarely, revert and cause outbreaks of its own, which is why wealthy countries switched to the injected vaccine and why a newer, more stable oral vaccine now exists.

What poliovirus does inside the body

Poliovirus is a small RNA virus (a virus whose genetic material is RNA instead of DNA) that spreads by the fecal-oral route. A child swallows a few viral particles from contaminated water, food, or hands, and the virus multiplies in the lining of the throat and intestine. For a more detailed look at the biology of the virus itself, see our explainer on how poliovirus works and why it paralyzes.

Most infections do nothing visible. The CDC's surveillance manual estimates that about 70% of infections in children are asymptomatic, roughly 24% cause a minor flu-like illness, 1 to 5% cause aseptic meningitis (inflammation around the brain and spinal cord without paralysis), and fewer than 1% cause flaccid paralysis. The World Health Organization puts the figure for irreversible paralysis at about 1 in 200 infections. That ratio is the reason polio looked random and capricious to the families who lived through it: for every child in a braces-and-crutches photograph, hundreds of others had carried the virus without knowing.

When the virus does reach the nervous system, it destroys motor neurons, the nerve cells in the spinal cord and brainstem that tell muscles to contract. Think of a motor neuron as the last relay in a chain of command. The brain may issue the order, but if the final relay is dead, the leg never moves. Muscles that lose their nerve supply cannot be reactivated, and the damage does not reverse.

Form of paralytic polio	Share of cases (U.S., 1969-1979)	What it affects
Spinal	79%	Limbs, trunk, diaphragm
Bulbospinal	19%	Breathing and swallowing plus limbs
Bulbar	2%	Brainstem nerves for swallowing, speech, breathing

Source: CDC, Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book), chapter on poliomyelitis.

The death rate depends on age and which nerves are hit. The CDC reports case-fatality rates of 2 to 5% in children, 15 to 30% in adolescents and adults, and 25 to 75% when the brainstem is involved. The WHO summarizes the same pattern in one line: 5 to 10% of people who become paralyzed die when the muscles that move the lungs stop working.

There was never a drug that undid this injury. Treatment was supportive, and the most famous support was mechanical. Philip Drinker and Louis Agassiz Shaw's "iron lung," a sealed metal cylinder that cycled air pressure around the patient's chest to force breathing, was first used clinically at Boston Children's Hospital in October 1928. It kept people alive, but it did nothing about the paralysis behind it.

Why the 1950s epidemics felt different

Polio was not new. The CDC's manual credits Michael Underwood with the first clinical description in England in 1789. What changed in the twentieth century was the pattern. In the nineteenth century, infants in crowded, unsanitary settings were exposed early, while still protected by antibodies passed from their mothers, and they usually developed lasting immunity with no symptoms. As sanitation improved, first exposure was delayed to later childhood and adulthood, when the infection was more likely to damage the nervous system. Cleaner cities, paradoxically, produced bigger paralysis epidemics. This is a standard explanation in the epidemiology of the disease, and it fits the CDC's age-specific fatality figures above, where older patients fare far worse.

The United States reached its peak in 1952, when more than 21,000 paralytic cases were reported, according to the CDC. Sources agree on about 3,145 deaths that year. Summer was the dangerous season. Public pools closed, parents kept children indoors, and hospitals set aside entire wards for respirator patients.

The money for the research came from public giving. The National Foundation for Infantile Paralysis, later the March of Dimes, funded laboratories and the large trial that followed. The practical consequence was that a vaccine was developed as a public project, with results announced to the public rather than to a company's shareholders.

The cell-culture advance that made a vaccine possible

Making a vaccine requires growing a lot of virus, and until the late 1940s poliovirus had been grown mainly in the nervous tissue of monkeys, which is expensive, dangerous, and impractical at scale. In 1948, John Enders, Thomas Weller, and Frederick Robbins at Children's Hospital Boston showed that poliovirus would multiply in cultured non-nervous human tissue. They shared the 1954 Nobel Prize in Physiology or Medicine for the work.

Cell culture did two things. It made large, relatively uniform batches of virus possible, and it let researchers observe the damage the virus did to cells in a dish, which gave them a way to test whether a serum or a vaccine neutralized it. A second piece of groundwork had come in 1949, when David Bodian and colleagues established that there were three distinct types of poliovirus. That mattered because immunity to one type does not protect against the others. Any workable vaccine would have to contain all three, which is why the injected and oral vaccines are both trivalent, or, in recent years, bivalent.

Think of the three types like three different keys on a ring. An antibody that fits type 1 does not fit the locks on types 2 and 3, so the vaccine has to hand the immune system a copy of each key.

How Salk built a vaccine from killed virus

Jonas Salk, working at the University of Pittsburgh, chose the conservative route: grow the virus in culture, then kill it with formaldehyde so it can no longer replicate while its outer proteins still look like the real thing. The immune system responds to those outer proteins, called antigens (the molecular features that antibodies recognize). Injected into muscle, the killed virus trains the body to make antibodies in the blood. If live virus later arrives, those antibodies bind it before it can reach the nervous system.

A useful analogy is a wanted poster. A killed-virus vaccine gives the immune system a detailed photograph of the culprit, without the culprit being present. The immune system memorizes the face, and if the real criminal shows up, patrols recognize it quickly.

The modern version of the vaccine follows the same logic. The CDC reports that current IPV is made from wild strains grown in Vero cells (a long-lived cell line originally derived from monkey kidney) and inactivated with formaldehyde. Salk's original formula was replaced in the late 1980s by an enhanced-potency version, standardized to 40, 8, and 32 D-antigen units (a measure of the immune-triggering protein) for types 1, 2, and 3. The U.S. schedule is now doses at 2 months, 4 months, 6 to 18 months, and 4 to 6 years.

Salk was confident enough in the product to test it on his own family. On May 16, 1953, according to the History of Vaccines project at the College of Physicians of Philadelphia, he injected himself, his wife, and their three sons with his experimental vaccine.

The 1954 field trial: the largest medical experiment of its time

The trial, led by Thomas Francis Jr. at the University of Michigan, began in spring 1954. Its scale is still striking. Starting at Franklin Sherman Elementary School in McLean, Virginia, on April 26, 1954, it eventually involved about 1.8 million children in 44 states. About 440,000 children received one or more injections, about 210,000 received a placebo (an injection that looks the same but contains no vaccine), and about 1.2 million served as unvaccinated controls.

The use of placebo and control groups is a large part of why the result was believed. Polio incidence swung wildly from year to year and place to place, so a drop in cases after vaccination could easily have been a coincidence. Comparing vaccinated children to similar unvaccinated children in the same season removed that ambiguity. Our explainer on why randomized trials are powerful covers the logic in general terms.

Francis announced the results on April 12, 1955, ten years to the day after the death of Franklin D. Roosevelt, the most famous polio survivor in the country. The vaccine was reported as safe and effective against paralytic polio. Later syntheses report efficacy of 60 to 70% against type 1 and over 90% against types 2 and 3, and 94% against the severest, bulbar form; the History of Vaccines project summarizes the headline as 80 to 90% effective against paralytic polio. The common claim that the first vaccine was 90 to 99% effective is not supported by those figures. Efficacy rose with later improvements in potency and with additional doses; published reviews report that three doses of modern IPV produce protective antibodies against all three types in at least 99% of recipients.

"Could you patent the sun?"

The same day, Salk appeared on Edward R. Murrow's CBS program See It Now. Asked who owned the patent, he answered that it belonged to the people and asked whether one could patent the sun. The line became a symbol of scientific altruism.

The historical record is a little more complicated than the quote. The historian Jane S. Smith, drawing on March of Dimes archives, found that the foundation had explored a patent and concluded the vaccine was not novel enough to qualify as a new invention. Salk's gesture was sincere, and it shaped how the public viewed him, but it was not the sacrifice of a patent that was ever likely to be granted.

When the safety net failed: the Cutter incident

Within hours of the announcement, the U.S. government licensed several manufacturers to produce the vaccine, and millions of doses went into arms. Then, in April 1955, children began to develop paralytic polio after vaccination. Investigators traced the cases to vaccine lots from Cutter Laboratories. The CDC and later historical accounts attribute the problem to incomplete inactivation: some lots that had passed required safety tests still contained live virus.

The best-documented toll comes from a review of the episode. About 120,000 children received the contaminated vaccine. Roughly 40,000 developed a mild, non-paralytic polio infection, 56 developed paralytic polio, and the virus then spread into their families and communities, causing 113 more paralytic cases. Ten deaths are known in total. Cutter withdrew its vaccine on April 27, 1955.

The consequences ran in two directions. Regulators lost confidence in the oversight process: the NIH's biologics laboratory had certified the vaccine, a congressional hearing in June 1955 concluded the agency had not scrutinized it enough, and several officials resigned or lost their posts. At the same time, the episode led to tighter manufacturing standards and testing requirements that apply to vaccines to this day. In the civil case Gottsdanker v. Cutter Laboratories, a jury found Cutter not negligent but liable for breach of implied warranty, an early step in the legal framework for vaccine injury.

The Cutter episode is a clean illustration of a point that recurs in vaccine history: a technology can be sound in design and still fail in manufacture, which is why production controls matter as much as the original idea.

How Sabin built a vaccine from weakened virus

Albert Sabin, at the University of Cincinnati, took a different path. Rather than killing the virus, he wanted to weaken it so it would still replicate in the body but no longer harm nerves. The CDC describes the Sabin strains as live attenuated viruses derived from wild poliovirus and weakened by repeated passage through cells. A virus passed through enough generations in one kind of cell adapts to that setting and loses fitness in the tissues it normally attacks, much like a wild animal bred for generations in a zoo loses its edge outdoors.

The resulting strains are swallowed as drops. They multiply in the gut, the same place wild virus multiplies, and the immune system responds in two places: in the blood, as with the injected vaccine, and in the intestinal lining, where it can block the wild virus at the door. Oral vaccine recipients also shed vaccine virus in stool for weeks, which can pass the weakened strains to close contacts and immunize them indirectly.

The first large trials of Sabin's strains were run in the Soviet Union, led by Mikhail Chumakov. In 1959, ten million Soviet children received the Sabin oral vaccine. In the United States, the CDC dates licensing of the monovalent types 1 and 2 vaccines to 1961, type 3 to 1962, and the trivalent oral vaccine (tOPV, covering all three types) to 1963.

Oral vaccine had practical advantages that mattered enormously in the field. It needed no needles, syringes, or trained injectors. A volunteer could give drops in a village or at a bus station. It cost less per dose. It also produced strong intestinal immunity, which blocks infection and onward spread, not only illness. Those features made it the workhorse of global eradication.

Comparing the two vaccines

Feature	Salk IPV (inactivated)	Sabin OPV (live attenuated)
Route	Injection	Oral drops
What it contains	Killed virus, all three types	Weakened live virus, three types (tOPV) or two types (bivalent since 2016)
Blood antibodies	Strong after full schedule; at least 99% protected after three doses	Roughly 50% after one trivalent dose; over 95% after three doses
Gut immunity	Weaker	Excellent
Can the vaccine virus spread?	No	Yes, to contacts
Can it cause polio?	No	Very rarely: vaccine-associated paralytic polio, about once per 2 to 3 million doses of tOPV (CDC)
Typical use today	Routine in the United States and most high-income countries	Outbreak response and many low-income settings

Sources: CDC Pink Book for the vaccine-associated paralysis rate and the IPV schedule; published immunogenicity reviews for the antibody figures.

What vaccination did to the numbers

In the United States, the decline was fast. The CDC reports 2,525 paralytic cases in 1960, five years after IPV licensing, and 61 in 1965. The last locally acquired wild-virus cases occurred in 1979, in an Amish community in several Midwestern states, seeded by an importation from the Netherlands.

Year	U.S. paralytic polio cases	Event
1952	More than 21,000	Epidemic peak
1955	Falling after licensure	IPV licensed
1960	2,525	IPV in wide use; oral vaccine licensing begins the next year
1965	61	Both vaccines in use
1979	Last locally acquired wild cases	Amish outbreak, imported
1980-1999	162 total (about 8 per year)	154 were vaccine-associated, 6 imported wild

Source: CDC Pink Book.

The 1980-1999 line is the part most often missed. In those two decades, 95% of the paralytic polio cases that occurred in the U.S. were caused by the live oral vaccine, not by wild virus. That is the arithmetic that drove the policy change. The CDC records a 1996 recommendation for a sequential schedule (injected vaccine first, then oral) to reduce vaccine-associated cases, and an exclusive-IPV recommendation at the end of the decade. The last U.S.-acquired vaccine-associated case was reported in 1999. When wild polio is gone from a country, using a vaccine that can occasionally cause polio no longer makes sense there.

The global eradication campaign

In 1988, the World Health Organization and its partners launched the Global Polio Eradication Initiative. At that time, the WHO estimates about 350,000 people were paralyzed by wild poliovirus each year across more than 125 endemic countries. The WHO now states that cases have fallen by more than 99% since then, and wild poliovirus remains endemic in just two countries.

The campaign relied on three tools used together: routine immunization of infants, mass "national immunization days" that deliver oral vaccine to every child under five in a short window, and surveillance. Surveillance is the less glamorous half. Because most infections are silent, health workers look for acute flaccid paralysis (sudden floppy weakness) in children, test the stool of those children, and also test sewage for poliovirus. Sewage testing catches circulation before it paralyzes anyone, which is how the program finds the virus in places where no case has been reported.

The milestones can be listed briefly.

• 2015: wild poliovirus type 2 declared eradicated.
• 2019: type 3 certified as eradicated by the Global Commission for the Certification of Poliomyelitis Eradication, announced on October 24, 2019 by the WHO. The last type 3 case was detected in northern Nigeria in 2012.
• August 25, 2020: the WHO's African region, with 47 countries, certified free of wild poliovirus after the last wild cases were detected in Nigeria in 2016.
• 2024: 99 wild poliovirus type 1 cases worldwide, 74 in Pakistan and 25 in Afghanistan, according to the WHO Emergency Committee statement of July 2025.
• 2025: the same committee counted 13 cases by early June, with 275 positive environmental samples, 245 of them in Pakistan and 30 in Afghanistan.

The number to hold onto is the difference between paralysis cases and positive sewage samples. Hundreds of positive environmental samples against a dozen or so paralysis cases is what the 1-in-200 ratio predicts: a lot of silent infection sits behind every visible case.

When the vaccine becomes the problem

The same property that makes the oral vaccine so useful, that it replicates in the gut and spreads, creates its one serious weakness. Weakened virus that circulates through a community with low immunity for long enough can mutate back toward a form that damages nerves. When it does, it is called circulating vaccine-derived poliovirus, or cVDPV. It behaves like wild poliovirus and can paralyze unvaccinated children.

Type 2 is the most common culprit. Wild type 2 was eradicated in 2015, so in 2016 the program withdrew the type 2 component from the oral vaccine, switching from trivalent to bivalent (types 1 and 3) vaccine. The idea was to stop introducing type 2 live virus into the environment. But children born after the switch had no type 2 immunity from the oral vaccine, and type 2 vaccine-derived viruses that were already circulating found fresh, susceptible populations. Published reviews of the program report that cVDPV2 cases rose from two in 2016 to more than 1,000 in 2020 (CDC counted 1,078; MMWR), and that in 2017 cVDPV cases outnumbered wild cases for the first time.

The response is a redesigned oral vaccine. Novel oral polio vaccine type 2 (nOPV2) was engineered to make the weakened virus genetically more stable so it is less likely to revert. It received WHO emergency use listing in November 2020, was first used in 2021, and gained WHO prequalification in December 2023. The WHO Emergency Committee reported about 1.65 billion doses administered by mid-2025. It also reported that 15 cVDPV2 emergence groups were detected in 2025 as of that meeting, against 30 in 2024, and that 36 countries were infected with cVDPV2, with or without evidence of local transmission. The same report identified 30 cVDPV2 emergences associated with nOPV2 itself, which shows that a more stable vaccine is not a risk-free one.

For readers, the important point is that the two problems are separate. Wild poliovirus type 1 is the original disease, limited to two countries. Vaccine-derived poliovirus is a downstream consequence of incomplete immunization, appearing in places where coverage is low. Both have the same ultimate fix, which is high immunization coverage, but the tools differ.

Why the last cases are the hardest

The WHO describes wild poliovirus type 1 as confined to the two endemic countries and, within them, concentrated in particular areas. In 2025 the Emergency Committee said transmission in Afghanistan's East Region had declined markedly in the first half of the year, while the most intense circulation remained in the southern cross-border corridor around the Quetta block in Pakistan and the South Region of Afghanistan.

Three features of the biology make the endgame difficult, independent of any political or logistical hurdle.

1. Silent spread. With about 99 of every 100 infections causing no paralysis, a population can carry virus for months before a case appears.
2. Gut immunity is what stops transmission. Injected vaccine protects the child but is less effective at stopping virus from replicating in the intestine, so places with heavy fecal contamination and low sanitation need high oral-vaccine coverage on top of routine injections.
3. Every missed child counts. Because the virus travels on contaminated hands and water, a small cluster of unvaccinated children can restart transmission in an otherwise well-vaccinated district.

Because of these features, eradication cannot be declared on the basis of a good year. It requires years of surveillance showing no virus in either children or sewage.

What polio taught medicine

Several practices that are now routine in medicine were hardened by the polio campaigns.

Large, controlled vaccine trials. The Francis trial set the pattern for evaluating a vaccine before mass use: a large population, a placebo, and an independent analysis. Our explainer on how vaccines work and why some people refuse them places that history in a broader context.

Cold chains. Oral vaccine must be kept cold from factory to village. Building and maintaining that chain of refrigerators, ice packs, and trained handlers was a large public-health project. The same infrastructure carries other vaccines, such as those for measles and rotavirus, which is also given by mouth.

Disease surveillance. Acute flaccid paralysis reporting and environmental sampling made it possible to find a virus that mostly hides. This network also watches other pathogens that can cause paralysis in children, such as enterovirus D68.

Eradication as a goal. Only one human disease has been eradicated so far: smallpox, which fell to a vaccine pioneered by Edward Jenner nearly two centuries earlier. Polio is the program that came closest to repeating it, and the effort has shown how much harder it is to finish a campaign than to start one.

For the broader immunology behind both approaches, see our guides to how vaccines train memory B cells and how vaccines work in the immune system, as well as the entry on vaccination as an invention.

Common misunderstandings

"The injected vaccine can give you polio." It cannot, because the virus in it is dead. The Cutter incident was a manufacturing failure, not a property of the vaccine's design, and it is the reason inactivation testing became far more rigorous.

"The oral vaccine is dangerous, so it should never be used." Vaccine-associated paralysis occurs about once per 2 to 3 million doses of the trivalent oral vaccine, according to the CDC, and vaccine-derived outbreaks occur in under-immunized populations. Against that, the oral vaccine's gut immunity and low cost were central to ending wild polio across most of the world. The right choice depends on whether wild virus is still circulating.

"Polio is gone, so we can stop vaccinating." Wild virus remains in two countries, and vaccine-derived virus has caused outbreaks in dozens more. Any unvaccinated community connected by travel to those places is at risk. The WHO's Director-General determined in July 2025 that the poliovirus situation still constitutes a Public Health Emergency of International Concern.

"The two vaccines were rivals, so one must be the right answer." The two researchers did compete, but the vaccines turned out to be complementary. IPV protects individuals and is safe in settings with no wild virus; OPV builds community-level gut immunity and is cheap to give in mass campaigns. Programs use both in different combinations.

"Vaccine immunity from the 1950s is the same as today's." The injected vaccine was upgraded in the late 1980s to an enhanced-potency formulation, and the oral vaccine's composition has changed (bivalent in 2016, with nOPV2 added for outbreak response).

The takeaway

Salk and Sabin gave the world two different answers to the same problem. One teaches the immune system with a harmless copy; the other lets a tamed virus run a rehearsal in the gut. Each excels where the other struggles, which is why the campaign that followed was a negotiation between safety and reach rather than a contest of winners and losers. What remains is the least glamorous stretch: finding every last chain of transmission, and replacing the live vaccine with safer versions without leaving a gap in protection. The decline from more than 21,000 paralytic cases in a single American year to a disease confined to two countries is a measure of what coordinated vaccination can do, and the remaining cases show how much of the work lies in reaching the last unvaccinated child.

FAQ

Q: How did Salk's vaccine work? A: Salk grew poliovirus in cell culture and inactivated it with formaldehyde so it could not replicate while its surface proteins stayed intact. Injected into muscle, the killed virus trains the immune system to produce antibodies against all three poliovirus types. Modern inactivated vaccine uses the same principle and is grown in Vero cells.

Q: How does Sabin's oral vaccine work? A: Sabin's vaccine contains live viruses weakened by repeated passage through cells. Swallowed as drops, they multiply in the gut and trigger immunity both in the blood and in the intestinal lining. Because vaccinated people shed the weakened virus, it can also immunize close contacts.

Q: Why are there two polio vaccines? A: The injected and oral vaccines have different strengths. The injected vaccine cannot cause polio and is the routine choice in countries free of wild virus. The oral vaccine is cheaper, needs no needles, and builds strong gut immunity, which makes it the main tool for mass campaigns and outbreak response.

Q: Has polio been eradicated? A: Not yet. Wild poliovirus types 2 and 3 have been declared eradicated, but type 1 remained in Afghanistan and Pakistan, which reported 99 cases in 2024. Vaccine-derived poliovirus, which arises from the oral vaccine in under-immunized populations, has also caused outbreaks in dozens of countries.

Q: Can the polio vaccine cause polio? A: The injected vaccine cannot, because the virus is killed. The oral vaccine can do so very rarely: the CDC puts vaccine-associated paralytic polio at about one case per 2 to 3 million doses of the trivalent oral vaccine. In under-vaccinated communities, weakened virus can also mutate and spread as vaccine-derived poliovirus.

Q: Why did the United States stop using the oral vaccine? A: Once wild polio was gone from the country, the oral vaccine became the main source of paralytic cases. Between 1980 and 1999, 154 of the 162 paralytic cases reported in the U.S. were vaccine-associated. The U.S. moved to an exclusive injected-vaccine schedule at the end of the 1990s.

Q: What was the Cutter incident? A: In April 1955, some lots of Salk vaccine made by Cutter Laboratories contained live poliovirus because of incomplete inactivation. About 120,000 children received it. Cases of paralytic polio followed in the vaccinated and in their contacts, with ten known deaths, and the episode led to stricter manufacturing and testing standards.

Sources

• World Health Organization. "Poliomyelitis" fact sheet. who.int/news-room/fact-sheets/detail/poliomyelitis
• Centers for Disease Control and Prevention. "Poliomyelitis," Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book), Chapter 18. cdc.gov/pinkbook
• History of Vaccines, College of Physicians of Philadelphia. "Polio timeline." historyofvaccines.org
• World Health Organization. "Statement of the forty-second meeting of the Polio IHR Emergency Committee," July 28, 2025. who.int
• Francis, T. Jr., et al. (1955). Evaluation of the 1954 poliomyelitis vaccine field trial. University of Michigan Poliomyelitis Vaccine Evaluation Center.
• Smith, J. S. (1990). Patenting the Sun: Polio and the Salk Vaccine. William Morrow.
• Enders, J. F., Weller, T. H., and Robbins, F. C. (1949). "Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues." Science, 109, 85-87.

---

Read next:

• Poliovirus: How It Works and Why It Paralyzes
• AI in Organ Transplantation: Matching, Allocation, and Saving More Lives
• Anesthesia Discovery: Pain-Free Surgery Explained
• Blood Type Classification: Understanding Transfusions Explained